New epilepsy therapies in development
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Epilepsy is a common brain disorder, characterized by spontaneous recurrent seizures, with associated neuropsychiatric and cognitive comorbidities and increased mortality. Although people at risk can often be identified, interventions to prevent the development of the disorder are not available. Moreover, in at least 30% of patients, epilepsy cannot be controlled by current antiseizure medications (ASMs). As a result of considerable progress in epilepsy genetics and the development of novel disease models, drug screening technologies and innovative therapeutic modalities over the past 10 years, more than 200 novel epilepsy therapies are currently in the preclinical or clinical pipeline, including many treatments that act by new mechanisms. Assisted by diagnostic and predictive biomarkers, the treatment of epilepsy is undergoing paradigm shifts from symptom-only ASMs to disease prevention, and from broad trial-and-error treatments for seizures in general to mechanism-based treatments for specific epilepsy syndromes. In this Review, we assess recent progress in ASM development and outline future directions for the development of new therapies for the treatment and prevention of epilepsy. Epilepsy is a common and debilitating brain disorder for which current antiseizure medications (ASMs) provide inadequate efficacy in around 30% of patients. In their Review, Pavel Klein and colleagues survey the diverse ASM pipeline, including new approaches to target specific epilepsy syndromes, and discuss strategies for disease prevention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Early Identification of Refractory Epilepsy
Kwan, P., & Brodie, M. J. (2000) · New England Journal of Medicine · doi:10.1056/nejm200002033420503 · Cited by 5,204 · cited 1×
“NKCC1 is expressed as two splice variants, NKCC1a and NKCC1b, which differ by alternative splicing of exon 21 (ref.”
Scheffer, I. E., Berkovic, S., Capovilla, G., Connolly, M. B., French, J., Guilhoto, L., Hirsch, E., Jain, S., Mathern, G. W., Moshé, S. L., et al. (2017) · Epilepsia · doi:10.1111/epi.13709 · Cited by 5,054 · cited 1×
“Our understanding of the pathophysiology of seizure types and epilepsy subtypes has evolved since its inception in the 1960s, and with this, classifications of seizures and epilepsies have been continuously updated on the basis of scientific progress 8 .”
Estimation of the burden of active and life-time epilepsy: a meta-analytic approach
Ngugi, A. K., Bottomley, C., Kleinschmidt, I., Sander, J. W., & Newton, C. R. (2010) · Epilepsia · doi:10.1111/j.1528-1167.2009.02481.x · Cited by 1,447 · cited 2×
“Epilepsy is one of the most common and disabling brain disorders, affecting approximately 1% of the population of all ages 1 , equating to ~3.3 million people in the USA and 70 million worldwide, with related psychiatric and neurocognitive impairments and other comorbidities, psychosocial decline…”
InfluentialBenzodiazepine actions mediated by specific γ-aminobutyric acidA receptor subtypes
Rudolph, U., Crestani, F., Benke, D., Brünig, I., Benson, J. A., Fritschy, J.-M., Martin, J. R., Bluethmann, H., & Möhler, H. (1999) · Nature · doi:10.1038/44579 · Cited by 1,172
A population-based study of seizures after traumatic brain injuries
Annegers, J. F., Hauser, W. A., Coan, S. P., & Rocca, W. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801013380104 · Cited by 1,090 · cited 1×
“Incidence of PTE varies by TBI severity, affecting 2.1%, 4.2% and 16.7% of patients with mild, moderate and severe TBI 30 years after TBI, where severe is defined as TBI with intracranial haemorrhage or >24 h post-traumatic loss of consciousness or amnesia 186 .”
InfluentialFrench, J. A., Lawson, J. A., Yapici, Z., Ikeda, H., Polster, T., Nabbout, R., Curatolo, P., de Vries, P. J., Dlugos, D. J., Berkowitz, N., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31419-2 · Cited by 764
A new benzodiazepine pharmacology
Möhler, H., Fritschy, J. M., & Rudolph, U. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.1.2 · Cited by 716
Partial recovery of visual function in a blind patient after optogenetic therapy
Sahel, J.-A., Boulanger-Scemama, E., Pagot, C., Arleo, A., Galluppi, F., Martel, J. N., Esposti, S. D., Delaux, A., de Saint Aubert, J.-B., de Montleau, C., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01351-4 · Cited by 700
The clinical landscape for AAV gene therapies
Kuzmin, D. A., Shutova, M. V., Johnston, N. R., Smith, O. P., Fedorin, V. V., Kukushkin, Y. S., van der Loo, J. C. M., & Johnstone, E. C. (2021) · Nature Reviews Drug Discovery · doi:10.1038/d41573-021-00017-7 · Cited by 503
GABA-based therapeutic approaches: GABAA receptor subtype functions
RUDOLPH, U., & MOHLER, H. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.10.003 · Cited by 499 · cited 1×
“GABA A receptor subunit diversity creates unique opportunities for selective pharmacological modulation of the BDZ site 90–92 . α1-Subunit-containing GABA A receptors were found to mediate sedation and hypnosis, antero-grade amnesia and part of the antiseizure activity of BDZs, whereas α2-and…”
Cited by
Targeting Kv7 Potassium Channels for Epilepsy
Perucca, E., & Taglialatela, M. (2025) · CNS Drugs · doi:10.1007/s40263-024-01155-3 · Cited by 43
“2/3 activator from China [169, 170].”
Carotenuto, L., Keminer, O., Carleo, G., Zaliani, A., Leo, A., Citraro, R., De Sarro, G., Dirkx, N., Kaji, M., Weckhuysen, S., et al. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70119 · Cited by 10
Wang, Z., Mei, H., Song, B., & Shi, Z. (2025) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2025.110638 · Cited by 6
Metadata
- Authors
- Klein, P., Kaminski, R. M., Koepp, M., & Löscher, W.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2024-07-22
- Volume
- 23
- Issue
- 9
- Pages
- 682-708
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W4400881231
- Cited by
- 154
- References
- 25
- FWCI
- 15.59
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: New epilepsy therapies in development. https://app.cochat.ai/papers/10.1038/s41573-024-00981-w
- The paper
- Klein, P., Kaminski, R. M., Koepp, M., & Löscher, W. (2024). New epilepsy therapies in development. Nature Reviews Drug Discovery. https://doi.org/10.1038/s41573-024-00981-w
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.